{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:41:35Z","timestamp":1784349695901,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grants from Shanghai Public Health Clinical Center","award":["KY-GW-2021-21"],"award-info":[{"award-number":["KY-GW-2021-21"]}]},{"name":"Grants from Shanghai Public Health Clinical Center","award":["KY-GW-2021-21"],"award-info":[{"award-number":["KY-GW-2021-21"]}]},{"name":"Grants from Shanghai Public Health Clinical Center","award":["KY-GW-2021-21"],"award-info":[{"award-number":["KY-GW-2021-21"]}]},{"name":"Grants from Hunan Provincial Health Commission","award":["20200855"],"award-info":[{"award-number":["20200855"]}]},{"name":"Grants from Hunan Provincial Health Commission","award":["20200855"],"award-info":[{"award-number":["20200855"]}]},{"name":"Grants from Hunan Provincial Health Commission","award":["20200855"],"award-info":[{"award-number":["20200855"]}]},{"name":"Grants from Hunan Provincial Health Commission","award":["20200855"],"award-info":[{"award-number":["20200855"]}]},{"name":"Grants from Hunan Provincial Health Commission","award":["20200855"],"award-info":[{"award-number":["20200855"]}]},{"name":"Shanghai Clinical key specialist Construction Project","award":["shslczdzk03002"],"award-info":[{"award-number":["shslczdzk03002"]}]},{"name":"Shanghai Clinical key specialist Construction Project","award":["shslczdzk03002"],"award-info":[{"award-number":["shslczdzk03002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770014"],"award-info":[{"award-number":["81770014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770014"],"award-info":[{"award-number":["81770014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>ESAT6-CFP10 (EC) skin test has been reported accurate and safe in identifying tuberculosis infection. We aimed to demonstrate the safety of EC skin test compared with tuberculin skin test (TST) in university freshmen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a double-blind, randomized, controlled clinical study in a university freshmen population with 16,680 participates in China, and finally 14,579 completed the study. About a half received an EC skin test and the others received TST. Adverse reactions were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 14,579 participants, 48.2% (7029\/14,579) were males. The average age was 18.1\u2009\u00b1\u20090.8 years and the average BMI was 20.9\u2009\u00b1\u20093.1\u00a0kg\/m<jats:sup>2<\/jats:sup>. 50.4% (7351\/14,579) participants received EC skin test and 49.6% (7228\/14,579) received TST. The EC group had significantly less adverse reactions compared with the TST group (21.3%, 1565\/7351 vs. 34.6%, 2499\/7228, <jats:italic>P\u2009=\u20090.000<\/jats:italic>). The most common adverse reactions for EC were bleeding (5.63%, 414), dermatodyschroia (4.27%, 314), induration (3.90%, 287), swelling (2.49%, 183), pain (1.59%, 117) and pruritus (1.48%, 109). Bleeding, dermatodyschroia, swelling and erythema were significantly less in EC group (<jats:italic>P\u2009&lt;\u20090.05<\/jats:italic>), while others were similar to those of TST.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>the EC skin test was safe in our cohort. And its incidence of total adverse drug reactions (ADRs) is less than that of TST. Most adverse reactions were mild or moderate, lasting less than 48\u00a0h and self-limiting. Considering the satisfactory diagnostic accuracy in identifying tuberculosis infection, the cost and safety, the EC skin test might be a potential candidate for replacing TST in high burden countries or those with routine BCG vaccination. Clinical Trials Registration. ChiCTR2000038622, Safety of the EC skin test to screen tuberculosis infection in two universities, compared with the tuberculin skin test: a double-blind, randomized, controlled trial. registered on 26\/09\/2020 at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">http:\/\/www.chictr.org.cn<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07765-w","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:03:38Z","timestamp":1665486218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety of a Novel ESAT6-CFP10 skin test compared with tuberculin skin test in a double-blind, randomized, controlled study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"7765_CR1","unstructured":"Organization WHO. Global tuberculosis report 2020. Geneva, Switzerland 2020, WHO, 2019."},{"issue":"10","key":"7765_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1473-3099(17)30402-4","volume":"17","author":"L Gao","year":"2017","unstructured":"Gao L, Li X, Liu J, Wang X, Lu W, Bai L, Xin H, Zhang H, Li H, Zhang Z, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17(10):1053\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7765_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1574-695X.2012.01002.x","volume":"66","author":"H Yang","year":"2012","unstructured":"Yang H, Kruh-Garcia NA, Dobos KM. Purified protein derivatives of tuberculin\u2013past, present, and future. FEMS Immunol Med Microbiol. 2012;66(3):273\u201380.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1","key":"7765_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3\u201320.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"7765_CR5","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.5588\/ijtld.12.0004","volume":"16","author":"YJ Jung","year":"2012","unstructured":"Jung YJ, Lyu J, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee KH, et al. Combined use of a TST and the T-SPOT(R).TB assay for latent tuberculosis infection diagnosis before anti-TNF-alpha treatment. Int J Tuberc Lung Dis. 2012;16(10):1300\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"Suppl 4","key":"7765_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/infdis\/jir410","volume":"204","author":"JZ Metcalfe","year":"2011","unstructured":"Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(Suppl 4):1120\u20139.","journal-title":"J Infect Dis"},{"issue":"3","key":"7765_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.201501-0199OC","volume":"192","author":"TC King","year":"2015","unstructured":"King TC, Upfal M, Gottlieb A, Adamo P, Bernacki E, Kadlecek CP, Jones JG, Humphrey-Carothers F, Rielly AF, Drewry P, et al. T-SPOT.TB Interferon-gamma Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals. Am J Respir Crit Care Med. 2015;192(3):367\u201373.","journal-title":"Am J Respir Crit Care Med"},{"key":"7765_CR8","doi-asserted-by":"crossref","unstructured":"Xu M, Lu W, Li T, Li J, Du W, Wu Q, Liu Q, Yuan B, Lu J, Ding X, et al: Sensitivity, specificity, and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China: two randomized, self-controlled, parallel-group phase 2b trials. Clin Infect Dis 2021.","DOI":"10.2139\/ssrn.3544842"},{"issue":"9","key":"7765_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1128\/CVI.00154-16","volume":"23","author":"F Li","year":"2016","unstructured":"Li F, Xu M, Zhou L, Xiong Y, Xia L, Fan X, Gu J, Pu J, Lu S, Wang G. Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial. Clin Vaccine Immunol. 2016;23(9):767\u201373.","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"7765_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","volume":"17","author":"RE Huebner","year":"1993","unstructured":"Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis. 1993;17(6):968\u201375.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"7765_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cmi.2016.07.015","volume":"22","author":"F Li","year":"2016","unstructured":"Li F, Xu M, Qin C, Xia L, Xiong Y, Xi X, Fan X, Gu J, Pu J, Wu Q, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect. 2016;22(10):889. e889-889 e816.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07765-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:07:27Z","timestamp":1665486447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07765-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7765"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07765-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from local ethics committees and the Center Hospital of Xiangtan City institutional review board. All participants aged 18 or over gave written informed consent before enrollment. For those aged under 18, their written informed consent was obtained from their parents or other legal guardians. Study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"780"}}